Clinical trial · Observational
Onco-haematology Vigilance Card
Impact of an Onco-haematology Vigilance Card in the Optimisation of the Town-hospital Relationship.
NCT04931329CI-TRIAL-00115981THERANOVA-LIMactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to show the interest of setting up a drug vigilance card in Oncology in order to reinforce patient safety, develop compliance and avoid drug interactions when the patient consults town professionals or other specialists.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematology | — | UNRESOLVED | — |
| Medical Oncology | — | UNRESOLVED | — |
| Molecular Targeted Therapies | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- measure patient satisfaction at 3 months
- timeFrame
- 3 months
- description
- Patient satisfaction will be evaluated using IBM computer usability satisfaction questionnaires published by James R. Lewis (https://doi.org/10.1080/10447319509526110)
Secondary outcomes (4)
- measure
- Measurement of caregiver satisfaction
- timeFrame
- 3 months
- description
- Caregiver satisfaction will be evaluated using IBM computer usability satisfaction questionnaires published by James R. Lewis (https://doi.org/10.1080/10447319509526110)
- measure
- Measurement of compliance reported by the GIRERD questionnaire
- timeFrame
- 3 months
- description
- patients will have to answer shorts questions on GIRERD\* questionnaire to evaluate their Medication compliance to oral anticancer drugs. \*X. Girerd, O. Hanon, K. Anagnostopoulos, C. Ciupek, J.J. Mourad, S. Consoli Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic Presse Med, 30 (2001), pp. 1044-1048
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * All patients treated at Limoges University Hospital in Medical Oncology department, receiving oral treatment (chemotherapy and/or targeted therapies) Exclusion Criteria: * All patients treated at Limoges University Hospital in Medical Oncology department, receiving hormone therapy or IV treatment only.
References
Publications (1)
- DERIVEDBoucheteil M, Leobon S, Baffert KA, Huet S, Darbas T, Le Brun-Ly V, Pestre J, Peyramaure C, Thuillier F, Venat L, Jost J, Touati M, Deluche E. [THERANOVA-LIM: Improving access to information on oral treatments for patients and pharmacists]. Bull Cancer. 2026 Mar;113(3):315-327. doi: 10.1016/j.bulcan.2025.10.005. Epub 2025 Dec 17. French. PMID 41412846